-
公开(公告)号：KR1020150039351A
公开(公告)日：2015-04-10
申请号：KR1020130117813
申请日：2013-10-02
Applicant: 충남대학교산학협력단 , 한남대학교 산학협력단
IPC: A61K31/7016 , A61K31/70 , A61K36/8968 , A61P19/10
CPC classification number: A61K36/73 , A23V2200/306 , A61K2236/33
Abstract: 본발명은매실추출물로부터분리된화합물을함유하는골다공증의예방또는치료용조성물에관한것으로서, 상기화합물들은조골세포의분화를유도하는반면, 파골세포는분화를억제하는효과가우수하여, 골다공증의치료에용이하게이용될수 있다.
Abstract translation: 本发明涉及一种含有从日本杏提取物中分离的用于预防或治疗骨质疏松症的化合物的组合物。 该化合物诱导成骨细胞的分化，但具有抑制破骨细胞分化的优异效果，因此可用于治疗骨质疏松症。
-
公开(公告)号：KR101449796B1
公开(公告)日：2014-10-13
申请号：KR1020120028259
申请日：2012-03-20
Applicant: 제주대학교 산학협력단 , 충남대학교산학협력단
IPC: A61K31/34 , A61K31/045 , A61K31/01 , A61P29/00
Abstract: 본 발명은 헤디치움 코로나리움(
Hedychium
coronarium ) 추출물 및 이들 유래 랍단 디터펜(Labdane-Type Diterpenes) 화합물의 용도에 관한 것으로, 이를 유효성분으로 함유하는 자가면역질환 및 패혈증 예방 및 치료용 조성물 또는 방법에 관한 것이다. 보다 구체적으로는, 지질다당류(lipopolysaccharide: LPS)에 의하여 자극된 염증성 사이토카인의 생성을 억제하는 헤디치움 코로나리움 추출물 및 이들 유래 랍단 디터펜 화합물의 용도에 관한 것이다.-
公开(公告)号：KR1020130106599A
公开(公告)日：2013-09-30
申请号：KR1020120028258
申请日：2012-03-20
Applicant: 제주대학교 산학협력단 , 충남대학교산학협력단
IPC: C07D307/02 , C07C39/23 , A61K31/34 , A61K36/906
CPC classification number: A61K36/906
Abstract: PURPOSE: A Labdane-type Diterpenoids Compound derived from Hedychium coronarium is provided to prevent the formation and activation of LPS-stimulated inflammatory cytokine, thereby treating and preventing sepsis and autoimmune diseases. CONSTITUTION: A Labdane-type Diterpenoids Compound derived from Hedychium coronarium for treating and preventing sepsis and autoimmune diseases contains the extract of Hedychium coronarium which suppresses the generation of LPS-stimulated Pro-inflammatory Cytokines. The LPS-stimulated inflammatory Cytokine is TNF-α, IL-6, or IL-12. The extract of Hedychium coronarium includes compounds as an active ingredient. The sepsis is systemic inflammatory reaction or endotoxic shock reaction.
Abstract translation: 目的：提供衍生自Hedychium coronarium的Labdane型二萜类化合物，以防止LPS刺激的炎性细胞因子的形成和活化，从而治疗和预防败血症和自身免疫性疾病。 构成：用于治疗和预防败血症和自身免疫疾病的源自Hedychium coronarium的Labdane型二萜类化合物含有抑制LPS刺激的促炎细胞因子的产生的Hedychium coronarium的提取物。 LPS刺激的炎性细胞因子是TNF-α，IL-6或IL-12。 枸杞提取物包括化合物作为活性成分。 败血症是全身炎症反应或内毒素休克反应。
-
34.发明授权섬오갈피나무 추출물 또는 이로부터 분리한 신규화합물을 유효성분으로 함유하는 탈모 방지 및 발모 개선용 조성물 有权组合物，其包含刺五加提取物或其衍生的新型化合物，用于预防秃发和改善毛发生长
公开(公告)号：KR101151555B1
公开(公告)日：2012-05-30
申请号：KR1020090037164
申请日：2009-04-28
Applicant: 제주대학교 산학협력단 , 충남대학교산학협력단
IPC: C08B37/00 , A61K36/254 , A61P17/14 , C07J7/00
Abstract: 본 발명은 섬오갈피나무 추출물 또는 이로부터 분리한 신규화합물을 유효성분으로 함유하는 탈모 방지 및 모발 생장 촉진 효과를 갖는 조성물에 관한 것으로, 상세하게는 본 발명의 섬오갈피나무 추출물 또는 이로부터 분리한 신규화합물 acankoreoside J가 모발의 성장에 중요한 역할을 하는 모유두세포(Dermal papilla cell)의 성장 증식을 촉진하여 모낭의 성장기를 유도하는 효과를 나타내므로, 탈모 방지 및 발모 개선용 피부외용 약학 조성물 및 화장료 조성물로 이용될 수 있다.
섬오갈피나무, acankoreoside J, 모낭, 탈모, 모유두세포-
公开(公告)号：KR101144613B1
公开(公告)日：2012-05-11
申请号：KR1020090106793
申请日：2009-11-06
Applicant: 충남대학교산학협력단
Abstract: PURPOSE: A pharmaceutical composition of BHT orally disintegrating tablet is provided to maximize stroke treatment effect. CONSTITUTION: A pharmaceutical composition of BHT orally disintegrating tablet contains 30-50 weight% of dried extract, 15-50 weight% of crospovidone, 5-30 weight% of crushed Arabian gum, and 0.1-2 weight% of glyceryl behenate. The dried extract is a mixture extract of Paeoniae Radix, Angelicae Gigantis Radix, Persicae Semen, Carthami Flos, Cnidii Rhizoma, Cinnamomi Ramulus, earth worm, Salviae Radix, Astragali Radix, Achyranthis Radix, Acori graminei Rhizoma and Polygalae Radix. The orally disintegrating tablet additionally contains one of microcrystalline cellulose and spray-dried lactose.
-
Patent Agency Ranking
公开(公告)号：KR101113202B1
公开(公告)日：2012-02-16
申请号：KR1020100088573
申请日：2010-09-09
Applicant: 충남대학교산학협력단 , 제주대학교 산학협력단
CPC classification number: A61K31/56 , A23L33/10 , A61K8/63 , A61K31/19 , Y10S424/81
Abstract: PURPOSE: A composition of triterpenoid for preventing and treating autoimmune diseases is provided to suppress IL-12, IL-6, and TNF-alpha. CONSTITUTION: A pharmaceutical composition for preventing and treating autoimmune diseases contains triterpenoid of chemical formula 1 or pharmaceutically acceptable salt thereof as an active ingredient. In chemical formula 1, R1 is CHO or CH_3; and R2 is O or CH_2. The composition additionally contains a carrier, excipient, disintegrant, sweetener, coating agent, lubricant, flavoring agent, anti-oxidant, buffer solution, diluents, dispersion agent, surfactant, or binder. The pharmaceutical composition is used in the form of a granule, powder, coating tablet, capsule, suppository, syrup, juice, suspension, emulsion, or liquid.
Abstract translation: 目的：提供用于预防和治疗自身免疫性疾病的三萜类化合物，以抑制IL-12，IL-6和TNF-α。 构成：用于预防和治疗自身免疫疾病的药物组合物含有化学式1的三萜化合物或其药学上可接受的盐作为活性成分。 在化学式1中，R1是CHO或CH_3; R2是O或CH_2。 该组合物还含有载体，赋形剂，崩解剂，甜味剂，包衣剂，润滑剂，调味剂，抗氧化剂，缓冲溶液，稀释剂，分散剂，表面活性剂或粘合剂。 药物组合物以颗粒，粉末，包衣片，胶囊，栓剂，糖浆，果汁，悬浮液，乳液或液体的形式使用。
-
公开(公告)号：KR101045027B1
公开(公告)日：2011-06-30
申请号：KR1020100107621
申请日：2010-11-01
Applicant: 충남대학교산학협력단
IPC: A61K31/403 , A61P9/00
CPC classification number: A61K31/404 , A23L29/035 , A23L29/045 , A23V2200/326
Abstract: PURPOSE: A composition containing Glycosmis stenocarpa(Drake) Tan-derived murrayafoline A is provided to enhance contraction of heart chamber muscle and to prevent and treat heart diseases. CONSTITUTION: A pharmaceutical composition for preventing or treating heart diseases contains murrayafoline A of chemical formula 1 as an active ingredient. A health food for preventing or treating heart diseases contains murrayafoline A of chemical formula 1. The health food is manufactured in the form of dairy products such as drinks, meat, sausage, and noodles; beverages; and supplementary nutritious products including alcoholic drinks and vitamin complex.
Abstract translation: 目的：提供含有Glycosmis stenocarpa（德雷克）Tan衍生的Murrayafoline A的组合物，以增强心室肌肉的收缩并预防和治疗心脏病。 构成：用于预防或治疗心脏病的药物组合物含有作为活性成分的化学式1的假单胞菌素A. 一种用于预防或治疗心脏病的保健食品含有化学式1的murrayafoline A.保健食品以饮料，肉类，香肠和面条等乳制品的形式制造。 饮料; 补充营养产品，包括酒精饮料和维生素复合物。
-
公开(公告)号：KR101039145B1
公开(公告)日：2011-06-03
申请号：KR1020100087227
申请日：2010-09-07
Applicant: 충남대학교산학협력단
IPC: A61K31/352 , A61K31/35 , A61K36/88 , A61P9/10
Abstract: PURPOSE: An organic solvent extract of Typha angustata is provided to suppress the proliferation of vascular smooth muscle cells and to prevent and treat circulatory diseases. CONSTITUTION: A pharmaceutical composition for preventing or treating circulatory diseases contains alcohol extract of Typha angustata. The pharmaceutical composition for preventing or treating circulatory diseases contains (2S)-naringenin of chemical formula 1 as an active ingredient. The compound of chemical formula 1 is isolated from the alcohol extract of Typha angustata. The circulatory diseases are hypertension, angina, myocardial infarction, cerebral infarction, or cardiac failure.
Abstract translation: 目的：提供香蒲香茅的有机溶剂提取物，以抑制血管平滑肌细胞的增殖，预防和治疗循环系统疾病。 构成：用于预防或治疗循环系统疾病的药物组合物含有香茅的酒精提取物。 用于预防或治疗循环系统疾病的药物组合物含有作为活性成分的化学式1的（2S） - 环糊精。 化学式1的化合物与香蒲香醇提取物分离。 循环系统疾病包括高血压，心绞痛，心肌梗死，脑梗死或心力衰竭。
-
39.发明公开흑인삼엽 가공 건조분말 또는 그 추출물을 유효성분으로함유하는 고병원성 조류 인플루엔자 바이러스의 예방 및치료용 조성물 无效一种包含黑皮诺辛酸的干燥叶粉的组合物或其分离的用于预防和治疗病原性AVIAN流感病毒的提取物
公开(公告)号：KR1020100038258A
公开(公告)日：2010-04-14
申请号：KR1020080097442
申请日：2008-10-04
Applicant: 충남대학교산학협력단
IPC: A61K36/258 , A61P31/16
Abstract: PURPOSE: A linear double strand RNA molecule reducing expression of different target genes is provided to induce gene silence regardless of inversion orientation of siRNA. CONSTITUTION: A linear double strand RNA molecule contains 2-10 short interference RNAs(siRNA) which are serially connected. The siRNA comprises 18-24 nucleotides. The linear double strand RNA molecule contains two successive siRNAs. Each strand contains two 3'-terminal nucleotides which is not formed in base pair. A recombinant expression vector comprises double strand DNA sequence expressing the linear double strand RNA molecule. The expression of a target gene is suppressed by introducing the recombinant expression vector and linear type double strand RNA molecule in cells.
Abstract translation: 目的：提供减少不同靶基因表达的线性双链RNA分子，以诱导基因沉默，而不管siRNA的倒置方向如何。 构成：线性双链RNA分子含有2-10个短连接RNA（siRNA），它们连接在一起。 siRNA包含18-24个核苷酸。 线性双链RNA分子含有两个连续的siRNA。 每条链含有两个未在碱基对中形成的3'末端核苷酸。 重组表达载体包含表达线性双链RNA分子的双链DNA序列。 通过在细胞中引入重组表达载体和线型双链RNA分子来抑制靶基因的表达。
-
公开(公告)号：KR1020210019051A
公开(公告)日：2021-02-19
申请号：KR1020210019439
申请日：2021-02-10
Applicant: 충남대학교산학협력단
IPC: A61K36/605 , A61P3/04 , A23L33/105 , A23L29/00
Abstract: 본발명은펙티넥스(pectinex)를처리하여생물전환된뽕나무잎 추출물을유효성분으로포함하는비만의예방또는치료용약학조성물에관한것이다. 상기추출물을지방세포에처리하는경우지방축적을저해하는효과가우수하며, 비만이유도된동물모델에투여하는경우비만동물의간, 부고환지방및 신장후지방의무게를감소시키는효과가우수하므로, 비만의예방또는치료용약학조성물로유용하게사용될수 있다.
-
-
-
-
-
-
-
-
-
Search Results
91
records
(took 0.046 seconds)
